Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis  

作　　者：Adel Khalifa Sultan Hamad 

机构地区：[1]Department of Electrophysiology,Mohammed bin Khalifa bin Salman Al Khalifa Cardiac Centre,Awali,Kingdom of Bahrain

出　　处：《Journal of Acute Disease》2022年第6期212-221,共10页急性病杂志（英文版）

摘　　要：Thrombotic complications appear to be a major predictor of death in COVID-19 patients,and multiple studies have shown that anticoagulants can help to improve the outcome.The Food and Drug Administration’s acceptance of non-vitamin K antagonist oral anticoagulants(NOACs)has sparked much excitement about their potential as a replacement for existing oral anticoagulants.NOACs target a single clotting factor,often activated factor X or thrombin,and involve the coagulation factor Xa inhibitors including apixaban,edoxaban,and rivaroxaban,and the thrombin inhibitor dabigatran.COVID-19 is an infectious disease that causes thrombotic events by inducing a pro-inflammatory and prothrombotic condition.This article provides a comprehensive overview of the mechanism behind enhanced thrombogenicity accompanying COVID-19,the clinical range of NOACs,and the role of NOACs in treatment of COVID-19 based on recent investigations and clinical trials.

关 键 词：ANTICOAGULANTS COVID-19 NOACs SARS-CoV-2 THROMBOSIS 

分 类 号：R563.1[医药卫生—呼吸系统]